The global hemodialysis and peritoneal dialysis market was valued at USD 112.4 billion in 2025 and is projected to grow to USD 219.05 billion by 2035, expanding at a 6.9 percent compound annual growth rate. Chronic kidney disease and end-stage renal disease, driven by rising diabetes and hypertension rates alongside aging populations, represent the dominant structural demand tailwind. Within this market, end-stage renal disease accounts for the largest disease indication segment, as ESRD patients require lifelong renal replacement therapy absent transplantation.
What is driving growth
Chronic kidney disease prevalence is rising globally at rates directly proportional to the incidence of type 2 diabetes and hypertension, accelerating especially in Asia Pacific and Latin America where urbanization is compressing traditional disease timelines. The US Renal Data System 2023 report identified 808,000 Americans living with ESRD, of whom 68 percent rely on dialysis, establishing a durable patient cohort requiring lifelong renal replacement therapy. Aging populations in developed markets and rapid health systems development in emerging markets both expand the addressable patient population. This epidemiological trajectory creates sustained demand across hemodialysis devices, peritoneal dialysis consumables, dialyzers, vascular access products, and clinical services.
Restraints and challenges
The per-patient annual cost of in-center hemodialysis in the United States at approximately USD 90,000 represents a primary access barrier in lower-income regions where government subsidies remain limited or absent. Home hemodialysis systems impose capital burdens on both patients and providers that slow adoption despite superior long-term economics. Reimbursement frameworks diverge substantially between in-center and home modalities outside North America and Western Europe, slowing the transition toward home-based care. Supply-chain volatility and regulatory compliance requirements add additional structural costs that manufacturers must absorb or pass to customers.
By service modality, in-center hemodialysis continues to hold the largest share, supported by established infrastructure of over 7,600 CMS-recognized US facilities and the global prevalence of clinic-based delivery models, though home hemodialysis services are forecast to grow at 11.4 percent compound annual growth through 2031, compared to in-center services at 6.5 percent. Hospitals remain the largest end-user category, given their role as primary admission points for newly diagnosed ESRD patients, acute kidney injury cases requiring continuous renal replacement therapy, and complex comorbidity patients requiring supervised treatment. Regional demand concentrates in North America, which accounted for 46.2 percent market share in 2025, with expansion accelerating across Asia Pacific and Latin America as urbanization increases disease burden and public health systems expand dialysis capacity.
Leading competitors including Fresenius Medical Care, B. Braun, Nipro Corporation, and Nikkiso Co. Ltd are investing heavily in digital platform integration, with Fresenius Medical Care’s Kinexus launch and Nikkiso’s FDA-cleared DBB-06 PRO exemplifying the industry shift toward connected care ecosystems.
Companies profiled
- Fresenius Medical Care
- Vantive
- B. Braun
- Nipro Corporation
- Nikkiso Co. Ltd
- Outset Medical
- AWAK Technologies
- Regional Outlook
For complete market sizing, forecasts, and competitive intelligence, read the full Hemodialysis & Peritoneal Dialysis Market — covering growth drivers, regional analysis, and leading company profiles through 2033.